RNS Number : 4186Q
Tiziana Life Sciences PLC
18 June 2020
Tiziana Life Sciences PLC
("Tiziana" or the "Company")
Directorate Change
London / New York, 18 June 2020 - Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS), the U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, announces Gregor MacRae is standing down as a director of the Company with immediate effect.
Gabriele Cerrone, Chairman of Tiziana, said "I thank Gregor for his contribution to the Board and the Company and wish him well in his other interests. We are currently in the process of recruiting a new, seasoned non-executive director with extensive NASDAQ audit committee experience and hope to make a formal announcement shortly".
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further enquiries:
United Kingdom:
|
Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder
|
+44 (0)20 7493 2379
|
|
Cairn Financial Advisers LLP (Nominated adviser)
Liam Murray / Jo Turner
|
+44 (0)20 7213 0880
|
|
Optiva Securities Limited (Broker)
Robert Emmet
|
+ 44 (0)20 3981 4173
|
United States:
Investors -
CORE IR
(516) 222-2560
ir@coreir.com
Media
Jules Abraham
CORE IR
(917) 885-7378
julesa@coreir.com
For more information go to http://www.tizianalifesciences.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the
United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com or visit
www.rns.com.
END
BOAGPUMCQUPUGCR
